WKRG

Recce Pharmaceuticals Announces Safety Committee Approves Faster Infusion Rate in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Independent Safety Committee approves the next cohort dosing of RECCE ® 327 (R327) at a faster infusion rate of 15 minutes of 3,000mg via intravenous (IV) administration R327 was shown to be safe and ...
Medscape

Avoid Preparing Infusions Using the Rule of 6 or Broselow Tape

A calculation error related to the Rule of 6 may have contributed to an infant's death recently when it led to a misplaced decimal point and the preparation of a ...
KTLA

Recce Pharmaceuticals Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Phase I/II study is tracking to meet primary endpoints RECCE ® 327 at 3,000mg over 15 minutes marks the fastest infusion rate of a high concentration Cohort fully recruited with remaining subjects to ...